Skip to main content
Mankind Pharma Limited logo

Mankind Pharma Limited — Investor Relations & Filings

Ticker · MANKIND ISIN · INE634S01028 LEI · 33580067G8AZ7S8NYA02 BSE.NS Manufacturing
Open in API
Filings indexed 397 across all filing types
Latest filing 2024-02-07 Share Issue/Capital Cha…
Country IN India
Listing BSE.NS MANKIND

About Mankind Pharma Limited

https://www.mankindpharma.com/

Mankind Pharma Limited focuses on the development, manufacturing, and marketing of a broad spectrum of pharmaceutical formulations and consumer healthcare products. The company’s portfolio spans various therapeutic areas, including anti-infectives, cardiovascular, gastrointestinal, dermatology, and respiratory health. It maintains a significant presence in the over-the-counter segment with brands such as Manforce, Prega News, and Gas-O-Fast. The organization operates a robust research and development infrastructure dedicated to creating affordable and accessible medicinal solutions. Its operational model leverages an extensive distribution network to ensure product availability across diverse geographic regions, prioritizing high-quality healthcare delivery and patient-centric innovation.

Recent filings

Filing Released Lang Actions
Updates
Share Issue/Capital Change Classification · 95% confidence The document is a formal notification addressed to stock exchanges regarding the intention of promoters to sell shares to comply with minimum public shareholding requirements. It references specific regulatory rules and SEBI circulars related to shareholding disclosures. The content focuses on the announcement of a proposed sale of promoter shares, including details of the shares to be divested and the timeline for the sale. There are no financial statements, earnings data, or detailed management analysis present. The document is not a full report but an announcement of a capital change event related to shareholding. Therefore, it fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding share issues or capital structure changes such as promoter share sales.
2024-02-07 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 90% confidence The document is a short notice dated February 2, 2024, addressed to stock exchanges regarding the availability of the audio recording of an investor conference call for Q3 FY24. It references a prior intimation about the investor conference call and provides a link to the audio recording. The content is an announcement about the call recording availability rather than the transcript or detailed content of the call itself. The document length is only 1306 characters, indicating it is a brief announcement rather than a full transcript or report. Therefore, it fits best under the category of Call Transcript (CT) since it relates to an earnings call, but since it only announces the availability of the audio recording and does not contain the transcript, it is more appropriate to classify it as a Regulatory Filing (RNS) as a general announcement under SEBI regulations. However, given the specific nature of the content about the investor conference call and the audio recording, the closest specific category is Call Transcript (CT) with moderate confidence, but the short length and announcement nature suggest Regulatory Filings (RNS) is more accurate. According to the rules, announcements about availability of recordings without the transcript text should be classified as Regulatory Filings (RNS).
2024-02-02 English
Copy of Newspaper Publication
Interim / Quarterly Report Classification · 95% confidence The document is dated February 1, 2024, and is addressed to stock exchanges in India (BSE Limited and National Stock Exchange of India Limited). It references Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs disclosure of financial results. The subject line clearly states it is a "Newspaper Publication of Consolidated Unaudited Financial Results for the quarter and nine months ended December 31, 2023." The document includes extracts of the consolidated unaudited financial results published in newspapers. This indicates it is an official announcement of quarterly financial results, specifically unaudited and for a partial fiscal period (quarter and nine months). The document is about financial results for a period shorter than a full fiscal year and contains substantive financial data. Therefore, it fits the definition of an Interim / Quarterly Report (IR). The document length (15,000 characters) and content suggest it is not merely a brief announcement or a certification but contains actual financial data. Hence, the classification is IR with high confidence. 9M 2024
2024-02-01 English
Investor Presentation
Regulatory Filings
2024-01-31 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated January 31, 2024, announcing the financial results for the quarter and nine months ended December 31, 2023. It includes detailed financial performance data such as revenue, EBITDA, PAT, EPS, and segmental revenue breakups. The document also mentions an upcoming earnings conference call. The content is typical of an Earnings Release, which provides key highlights of quarterly or periodical financial results. It is not a full annual or interim report, nor a transcript or presentation. The document is about 10,415 characters, which is consistent with a detailed earnings release rather than a brief announcement or a full report. Therefore, the appropriate classification is Earnings Release (ER). Q3 2024
2024-01-31 English
Outcome of Board Meeting
Regulatory Filings
2024-01-31 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.